Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ubrogepant
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : UBRELVY® (Ubrogepant), is an orally administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the acute treatment of migraine with or without aura in adults that is an option for a wide range of patients who experience migrain...
Product Name : Ubrelvy
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 09, 2022
Lead Product(s) : Ubrogepant
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ubrogepant
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AbbVie's investigational preventive treatment of migraine in adults who meet criteria for episodic migraine, as well as data on UBRELVY® (ubrogepant) and BOTOX® (onabotulinumtoxinA).
Product Name : Ubrelvy
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 26, 2021
Lead Product(s) : Ubrogepant
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable